<p>Johnson & Johnson and AstraZeneca are conducting early research into whether modifications to their Covid-19 vaccines could eliminate or reduce the risk of rare blood clots linked to the shots, the <em>Wall Street Journal</em> reported, citing people close to the process.</p>.<p>WSJ on Tuesday reported that outside scientists and AstraZeneca's partner, the University of Oxford, were also involved in the efforts.</p>.<p>AstraZeneca and J&J did not immediately respond to <em>Reuters'</em> request for comment.</p>.<p>Both vaccines have been linked to the risk of blood clots, though regulators have said that benefits of the vaccines largely outweigh the risks.</p>
<p>Johnson & Johnson and AstraZeneca are conducting early research into whether modifications to their Covid-19 vaccines could eliminate or reduce the risk of rare blood clots linked to the shots, the <em>Wall Street Journal</em> reported, citing people close to the process.</p>.<p>WSJ on Tuesday reported that outside scientists and AstraZeneca's partner, the University of Oxford, were also involved in the efforts.</p>.<p>AstraZeneca and J&J did not immediately respond to <em>Reuters'</em> request for comment.</p>.<p>Both vaccines have been linked to the risk of blood clots, though regulators have said that benefits of the vaccines largely outweigh the risks.</p>